Tuberculosis and COVID-19 Dually Affect Human Th17 Cell Immune Response

COVID-19 infection not only profoundly impacts the detection of tuberculosis infection (Tbc) but also affects modality in tuberculosis patient immune response. It is important to determine immune response alterations in latent tuberculosis infection as well as in SARS-CoV-2-infected tuberculosis patients. Such changes may have underlying effects on the development and course of further tuberculosis. Here, we aimed to review the characteristics of immune response in TB patients or convalescent COVID-19 patients with latent TB infection (LTBI). Materials and Methods. We analyzed the features of immune response in tuberculosis and COVID-19 patients. For this, we analyzed publications released from December 2019 to March 2023; those which were published in accessible international databases (“Medline”, “PubMed”, “Scopus”) and with keywords such as “COVID-19”, “SARS-CoV-2”, “tuberculosis”, “pulmonary tuberculosis”, “latent tuberculosis infection”, “Treg”, “follicular Treg”, and “Treg subsets”, we considered. Results. Through our analysis, we found that tuberculosis patients who had been infected with COVID-19 previously and elevated Th1 and Th2 cell levels. High levels of Th1 and Th2 cells may serve as a positive marker, characterizing activated immune response during TB infection. COVID-19 or post-COVID-19 subjects showed decreased Th17 levels, indicating a lack of tuberculosis development. Moreover, the typical course of tuberculosis is associated with an increase in Treg level, but COVID-19 contributes to a hyperinflammatory response. Conclusion. According to the data obtained, the course of tuberculosis proceeds in a dissimilar way due to the distinct immune response, elicited by SARS-CoV-2. Importantly, the development of active tuberculosis with a severe course is associated with a decline in Treg levels. Both pathogens lead to disturbed immune responses, increasing the risk of developing severe TB. The insights and findings of this paper may be used to improve the future management of individuals with latent and active tuberculosis.

[1]  Xia Li,et al.  T follicular helper cells and T follicular regulatory cells in autoimmune diseases , 2023, Frontiers in Immunology.

[2]  A. Rabaan,et al.  Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities with a Special Focus on Long COVID , 2023, Vaccines.

[3]  N. Arsenijević,et al.  Increased Pro Th1 And Th17 Transcriptional Activity In Patients With Severe COVID-19 , 2023, International journal of medical sciences.

[4]  R. Al-Kayali,et al.  Activation of tuberculosis in recovered COVID-19 patients: a case report , 2023, Annals of medicine and surgery.

[5]  Y. Shoenfeld,et al.  Identification of autoimmune markers in pulmonary tuberculosis , 2023, Frontiers in Immunology.

[6]  Y. Okada,et al.  A sex-biased imbalance between Tfr, Tph, and atypical B cells determines antibody responses in COVID-19 patients , 2023, Proceedings of the National Academy of Sciences of the United States of America.

[7]  G. Gore,et al.  A scoping review on the risk of tuberculosis in specific population groups: can we expand the World Health Organization recommendations? , 2023, European Respiratory Review.

[8]  N. Berhe,et al.  Tuberculosis in individuals who recovered from COVID-19: A systematic review of case reports , 2022, PloS one.

[9]  Yan-Tong Xu,et al.  Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives , 2022, Frontiers in Immunology.

[10]  Theresa L. Chang,et al.  ACE2-Independent Alternative Receptors for SARS-CoV-2 , 2022, Viruses.

[11]  H. Alwafi,et al.  Disseminated Tuberculosis Post COVID-19 Infection: A Case Report , 2022, Cureus.

[12]  R. Krüger,et al.  Performance of QuantiFERON-TB Gold Plus assays in paediatric tuberculosis: a multicentre PTBNET study , 2022, Thorax.

[13]  I. Kudryavtsev,et al.  Heterogenous CD8+ T Cell Maturation and ‘Polarization’ in Acute and Convalescent COVID-19 Patients , 2022, Viruses.

[14]  D. R. Soriano-Moreno,et al.  Immune responses in COVID-19 and tuberculosis coinfection: A scoping review , 2022, Frontiers in Immunology.

[15]  T. Karonova,et al.  Cytokine Storm Signature in Patients with Moderate and Severe COVID-19 , 2022, International journal of molecular sciences.

[16]  M. Mirsaeidi,et al.  SARS-CoV-2 cell entry beyond the ACE2 receptor , 2022, Molecular Biology Reports.

[17]  José Domínguez,et al.  Advances in diagnostic tools for respiratory tract infections: from tuberculosis to COVID-19 – changing paradigms? , 2022, ERJ Open Research.

[18]  Irina Isakova-Sivak,et al.  Dysregulated Immune Responses in SARS-CoV-2-Infected Patients: A Comprehensive Overview , 2022, Viruses.

[19]  S. Hasnain,et al.  COVID-19 and tuberculosis: the double whammy of respiratory pathogens , 2022, European Respiratory Review.

[20]  I. Kudryavtsev,et al.  Tuberculosis and autoimmunity: Common features. , 2022, Tuberculosis.

[21]  K. Saad,et al.  Association of follicular helper T and follicular regulatory T cells with severity and hyperglycemia in hospitalized COVID-19 patients , 2022, Virulence.

[22]  Yuming Li,et al.  Follicular Helper T Cells in Pulmonary Tuberculosis: A Retrospective Study. , 2022, Iranian journal of immunology : IJI.

[23]  F. De Maio,et al.  The Dark Side of the COVID-19 Treatments on Mycobacterium Tuberculosis Infection , 2022, Mediterranean journal of hematology and infectious diseases.

[24]  L. Fattorini,et al.  Mycobacterium tuberculosis and SARS-CoV-2 Coinfections: A Review , 2022, Frontiers in Microbiology.

[25]  M. Balbín,et al.  Clinical and Epidemiological Correlates of Low IFN-Gamma Responses in Mitogen Tube of QuantiFERON Assay in Tuberculosis Infection Screening During the COVID-19 Pandemic: A Population-Based Marker of COVID-19 Mortality? , 2022, Archivos de Bronconeumología.

[26]  J. Domínguez,et al.  Molecular and Cellular Mechanisms of M. tuberculosis and SARS-CoV-2 Infections—Unexpected Similarities of Pathogenesis and What to Expect from Co-Infection , 2022, International journal of molecular sciences.

[27]  Guangyu Zhao,et al.  Peptide-Based Vaccines for Tuberculosis , 2022, Frontiers in Immunology.

[28]  A. Apt,et al.  Pleiotropic Effect of IL-6 Produced by B-Lymphocytes During Early Phases of Adaptive Immune Responses Against TB Infection , 2022, Frontiers in Immunology.

[29]  Ali I. Al-Gareeb,et al.  Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality , 2022, International Immunopharmacology.

[30]  I. Kudryavtsev,et al.  Alterations in B Cell and Follicular T-Helper Cell Subsets in Patients with Acute COVID-19 and COVID-19 Convalescents , 2021, Current issues in molecular biology.

[31]  Prince Sharma,et al.  COVID-19 Diagnosis: Current and Future Techniques , 2021, International Journal of Biological Macromolecules.

[32]  M. Farzan,et al.  Mechanisms of SARS-CoV-2 entry into cells , 2021, Nature reviews. Molecular cell biology.

[33]  D. San Segundo,et al.  Innate and Adaptive Immune Assessment at Admission to Predict Clinical Outcome in COVID-19 Patients , 2021, Biomedicines.

[34]  S. Babu,et al.  Latent tuberculosis co-infection is associated with heightened levels of humoral, cytokine and acute phase responses in seropositive SARS-CoV-2 infection , 2021, Journal of Infection.

[35]  H. Yanai,et al.  Circulating IgA/IgG memory B cell against Mycobacterium tuberculosis dormancy-associated antigens Rv2659c and Rv3128c in active and latent tuberculosis. , 2021, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[36]  K. Chung,et al.  Increased Th1 Cells with Disease Resolution of Active Pulmonary Tuberculosis in Non-Atopic Patients , 2021, Biomedicines.

[37]  P. Mertz,et al.  Granulomatous manifestations associated with COVID19 infection: Is there a link between these two diseases? , 2021, Autoimmunity Reviews.

[38]  Y. Shoenfeld,et al.  New laboratory criteria of the autoimmune inflammation in pulmonary sarcoidosis and tuberculosis. , 2021, Clinical immunology.

[39]  A. Sette,et al.  Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2 , 2021, International Journal of Infectious Diseases.

[40]  Y. Shoenfeld,et al.  Immunogenetic Predictors of Severe COVID-19 , 2021, Vaccines.

[41]  Victor G. Puelles,et al.  Clonal expansion and activation of tissue-resident memory-like TH17 cells expressing GM-CSF in the lungs of patients with severe COVID-19 , 2021, Science Immunology.

[42]  J. Pedrosa,et al.  Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia , 2021, Frontiers in Immunology.

[43]  A. Tzankov,et al.  Reaktionsmuster der lokoregionären Lymphknoten im Abflussgebiet von COVID-19-Lungen , 2021, Der Pathologe.

[44]  M. Khayat,et al.  COVID-19 promoting the development of active tuberculosis in a patient with latent tuberculosis infection: A case report , 2021, Respiratory Medicine Case Reports.

[45]  M. Dimopoulos,et al.  Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications , 2021, Journal of biomedical science.

[46]  J. Routy,et al.  Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System , 2020, Frontiers in Immunology.

[47]  F. Garrido,et al.  Negative Clinical Evolution in COVID-19 Patients Is Frequently Accompanied With an Increased Proportion of Undifferentiated Th Cells and a Strong Underrepresentation of the Th1 Subset , 2020, Frontiers in Immunology.

[48]  M. Ono,et al.  T-cell dysregulation in COVID-19 , 2020, Biochemical and Biophysical Research Communications.

[49]  D. Raoult,et al.  Evaluation of the Panbio COVID-19 Rapid Antigen Detection Test Device for the Screening of Patients with COVID-19 , 2020, Journal of Clinical Microbiology.

[50]  R. Valenta,et al.  Immunological imprint of COVID‐19 on human peripheral blood leukocyte populations , 2020, Allergy.

[51]  A. d’Arminio Monforte,et al.  Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness , 2020, Frontiers in Immunology.

[52]  F. Fathi,et al.  Immune system changes during COVID-19 recovery play key role in determining disease severity , 2020, International journal of immunopathology and pharmacology.

[53]  Xiaowen Jiang,et al.  Characteristics of immune cells and cytokines in patients with coronavirus disease 2019 in Guangzhou, China , 2020, Human Immunology.

[54]  T. Jin,et al.  Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals. , 2020, The Journal of clinical investigation.

[55]  A. Sattler,et al.  SARS-CoV-2 specific T-cell responses and correlations with COVID-19 patient predisposition. , 2020, The Journal of clinical investigation.

[56]  Kelsey K. Finn,et al.  Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19 , 2020, Cell.

[57]  Guoping Wang,et al.  Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19 Patients , 2020, Current Medical Science.

[58]  M. Girardis,et al.  Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID-19 patients with pneumonia. , 2020, European journal of immunology.

[59]  M. Addo,et al.  Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease , 2020, Immunity.

[60]  P. Durando,et al.  The diagnosis of latent tuberculosis infection (LTBI): currently available tests, future developments, and perspectives to eliminate tuberculosis (TB) , 2020, La Medicina del lavoro.

[61]  H. Ljunggren,et al.  Expansion of SARS-CoV-2–Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients , 2020, The Journal of Immunology.

[62]  R. Scarpa,et al.  Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms , 2020, Autoimmunity Reviews.

[63]  Hans Clevers,et al.  SARS-CoV-2 productively infects human gut enterocytes , 2020, Science.

[64]  R. Woods,et al.  Neutrophil extracellular traps in COVID-19. , 2020, JCI insight.

[65]  J. M. Crawford,et al.  Targeting potential drivers of COVID-19: Neutrophil extracellular traps , 2020, The Journal of experimental medicine.

[66]  J. Low,et al.  Critically ill COVID‐19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability , 2020, American journal of hematology.

[67]  A. Zangrillo,et al.  Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis , 2020, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[68]  R. Giacomelli,et al.  Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? , 2020, Autoimmunity Reviews.

[69]  Yong-tang Zheng,et al.  Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[70]  Xilong Deng,et al.  Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China , 2020, medRxiv.

[71]  S. Tang,et al.  COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease. , 2020, The American journal of Chinese medicine.

[72]  Dandan Wu,et al.  TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib , 2020, Journal of Microbiology, Immunology and Infection.

[73]  B. Corleis,et al.  Early dynamics of innate immunity during pulmonary tuberculosis. , 2020, Immunology letters.

[74]  P. Cardona,et al.  Regulatory T Cells in Mycobacterium tuberculosis Infection , 2019, Front. Immunol..

[75]  Xinchun Chen,et al.  MTB driven B cells producing IL-35 and secreting high level of IL-10 in the patients with active pulmonary tuberculosis. , 2019, Molecular immunology.

[76]  Анна Андреевна Старшинова,et al.  Нарушения в субпопуляционном составе Т-хелперов 17 и фолликулярных Т-хелперов у больных туберкулезом легких , 2019 .

[77]  I. Lyadova,et al.  Cell Differentiation Degree as a Factor Determining the Role for Different T-Helper Populations in Tuberculosis Protection , 2019, Front. Immunol..

[78]  N. Karandikar,et al.  Human Tc17 cells harbor potent immune suppressive potential, whereas Tc1 cells lack suppressive ability , 2019, Journal of Immunology.

[79]  Asma Ahmed,et al.  Circulating HLA-DR+CD4+ effector memory T cells resistant to CCR5 and PD-L1 mediated suppression compromise regulatory T cell function in tuberculosis , 2018, PLoS pathogens.

[80]  I. Lyadova,et al.  Th1, Th17, and Th1Th17 Lymphocytes during Tuberculosis: Th1 Lymphocytes Predominate and Appear as Low-Differentiated CXCR3+CCR6+ Cells in the Blood and Highly Differentiated CXCR3+/−CCR6− Cells in the Lungs , 2018, The Journal of Immunology.

[81]  V. Zhuravlev,et al.  A comparison of intradermal test with recombinant tuberculosis allergen (diaskintest) with other immunologic tests in the diagnosis of tuberculosis infection , 2018, International journal of mycobacteriology.

[82]  Chong-Jen Yu,et al.  Decreased T helper 17 cells in tuberculosis is associated with increased percentages of programmed death ligand 1, T helper 2 and regulatory T cells , 2017, Respiratory Research.

[83]  T. Ottenhoff,et al.  Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases , 2017, Front. Immunol..

[84]  M. Tebruegge,et al.  Tuberculosis: An Infection-Initiated Autoimmune Disease? , 2016, Trends in immunology.

[85]  G. Walzl,et al.  Phenotypic analysis of peripheral B cell populations during Mycobacterium tuberculosis infection and disease , 2016, Journal of Inflammation.

[86]  Kun Xu,et al.  Genetic polymorphisms of IL-17A, IL-17F, TLR4 and miR-146a in association with the risk of pulmonary tuberculosis , 2016, Scientific Reports.

[87]  Changyou Wu,et al.  Mycobacterium tuberculosis-Specific IL-21+IFN-γ+CD4+ T Cells Are Regulated by IL-12 , 2016, PloS one.

[88]  T. Muramatsu.  Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners , 2015, Journal of biochemistry.

[89]  I. Lyadova,et al.  Th1 and Th17 Cells in Tuberculosis: Protection, Pathology, and Biomarkers , 2015, Mediators of inflammation.

[90]  J. Rangel-Moreno,et al.  Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge , 2014, Mucosal Immunology.

[91]  Xiao-lian Zhang,et al.  CFP10 and ESAT6 aptamers as effective Mycobacterial antigen diagnostic reagents. , 2014, The Journal of infection.

[92]  T. Nutman,et al.  Decreased Frequencies of Circulating CD4+ T Follicular Helper Cells Associated with Diminished Plasma IL-21 in Active Pulmonary Tuberculosis , 2014, PloS one.

[93]  J. Kolls,et al.  Unexpected Role for IL-17 in Protective Immunity against Hypervirulent Mycobacterium tuberculosis HN878 Infection , 2014, PLoS pathogens.

[94]  K. Dheda,et al.  Regulatory T cells attenuate mycobacterial stasis in alveolar and blood-derived macrophages from patients with tuberculosis. , 2013, American journal of respiratory and critical care medicine.

[95]  M. Selman,et al.  CXCR5⁺ T helper cells mediate protective immunity against tuberculosis. , 2013, The Journal of clinical investigation.

[96]  V. García,et al.  IL‐17 and IFN‐γ expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease , 2012, Journal of leukocyte biology.

[97]  Zhaohui Zheng,et al.  Role of the frequency of blood CD4(+) CXCR5(+) CCR6(+) T cells in autoimmunity in patients with Sjögren's syndrome. , 2012, Biochemical and biophysical research communications.

[98]  Chung-Jen Chen,et al.  Prognostic values of serum IP-10 and IL-17 in Patients with Pulmonary Tuberculosis , 2011, Disease markers.

[99]  Xinchun Chen,et al.  Reduced Th17 response in patients with tuberculosis correlates with IL-6R expression on CD4+ T Cells. , 2010, American journal of respiratory and critical care medicine.

[100]  Hiroki Sato,et al.  CD147/EMMPRIN Acts as a Functional Entry Receptor for Measles Virus on Epithelial Cells , 2010, Journal of Virology.

[101]  R. Casetti,et al.  Characterization of regulatory T cells identified as CD4+CD25highCD39+ in patients with active tuberculosis , 2009, Clinical and experimental immunology.

[102]  J. Ernst,et al.  Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs , 2008, The Journal of experimental medicine.

[103]  R. Colbert,et al.  B-Cell Depletion in Wegener’s Granulomatosis , 2008, Clinical reviews in allergy & immunology.

[104]  J. Ernst,et al.  Mycobacterium tuberculosis Infects Dendritic Cells with High Frequency and Impairs Their Function In Vivo1 , 2007, The Journal of Immunology.

[105]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[106]  W. Selby,et al.  Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells , 2006, The Journal of experimental medicine.

[107]  A. Lalvani,et al.  Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. , 2006, American journal of respiratory and critical care medicine.

[108]  P. Allavena,et al.  Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s , 1998, The Journal of experimental medicine.

[109]  A. Yadegar,et al.  Significant changes of CD4, FOXP3, CD25, and IL6 expression level in Iranian COVID-19 patients , 2020, Gastroenterology and hepatology from bed to bench.

[110]  V. Jarlier,et al.  Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study. , 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.